Citations

Showing 10 of 107964 citations.

Frontline treatment of multiple myeloma
Fonseca, Rafaël , Fonseca, Rafael

Mayo Clinic

Hematology | June 21, 2012 | Volume: 17 | Issue: sup1 | Pages: s101-s104

10.1179/102453312x13336169156096 | PMID 22507793 Get It

New developments in the management of diffuse large B-cell lymphoma
Habermann, Thomas M.

Mayo Clinic

Hematology | June 21, 2012 | Volume: 17 | Issue: sup1 | Pages: s93-s97

10.1179/102453312x13336169156014 | PMID 22507791 Get It

The Development of Ascending Aortic Aneurysms After Elective Aortic Valve Replacement With St Jude Mechanical Valve Prosthesis in the Bicuspid Patient
Cohoon, Kevin P. , Foley, Jillian, Dieter, Robert S., Bakhos, Mamdouh, Schwartz, Jeffrey

Mayo Clinic

Angiology | June 21, 2012 | Volume: 64 | Issue: 5 | Pages: 379-384

10.1177/0003319712450504 | PMID 22717597 Get It

The association between bicuspid aortic valve (BAV) and ascending aorta aneurysm is well described. Replacement of the ascending aorta is now being considered at 4.5 cm. We identified patients confirmed with BAV who underwent elective aortic valve replacement (AVR) with a mechanical St Jude Bioprosthesis from 1994 to 2000 who were ≤65 years of age at the time of surgery. Follow-up imaging was obtained by computed tomography (CT) angiography or echocardiography. A total of 225 patients who underwent AVR were identified; 60 patients had a BAV. Of all, 36 (60%) patients with BAV returned for follow-up imaging of their ascending aorta. Eight patients (22%) had diameters classifiable as aneurysmal (>4.5 cm) that developed within 9.6 ± 4.1 years from implant and requiring surgery. Of all, 7 patients (12%) died within 5.9 ± 2.5 years from their implant date. Lifelong serial monitoring of the ascending aorta for patients with BAV should be the standard of care.
Thrombosis in multiple myeloma (MM)
Cesarman‐Maus, Gabriela , Braggio, Esteban , Fonseca, Rafaël , Braggio, Esteban , Cesarman-Maus, Gabriela , Fonseca, Rafael

Mayo Clinic

Hematology | June 21, 2012 | Volume: 17 | Issue: sup1 | Pages: s177-s180

10.1179/102453312x13336169156933 | PMID 22507814 Get It

A comprehensive analysis of hemoglobin variants by high‐performance liquid chromatography (HPLC)
Szuberski, Jessica, Oliveira, Jennifer L. , Hoyer, J. D., Herrick, Jennifer L.

Mayo Clinic

International Journal of Laboratory Hematology | June 20, 2012 | Volume: 34 | Issue: 6 | Pages: 594-604

10.1111/j.1751-553x.2012.01440.x | PMID 22713122 Get It

SummaryIntroductionHigh‐performance liquid chromatography (HPLC) is a method commonly used for the detection of hemoglobin (Hb) variants. In addition to providing precise quantitation of Hb A2 and Hb F, the reported retention time and peak shape of a high number of hemoglobin (Hb) variants are very helpful for presumptive identification. However, there is a scarcity of summarized data in the literature of the mobility of Hb variants on this method.MethodsA total of 383 Hb variants were studied on the Bio‐Rad Variant ™ Classic HPLC instrument. Hb variant identification used a number of methods, including confirmation by DNA sequencing in at least one case for all alpha and beta chain Hb variants.ResultsRetention time data and the number of occurrences of each Hb variant were obtained. This showed that rare Hb variants can have similar retention times to the five most common alpha or beta chain Hb variants.ConclusionHPLC is a very powerful tool in the evaluation of Hb variants, particularly when combined with other methods. However, it should not be used as a stand‐alone method for definitive identification of Hb variants.
Acellular Fetal Bovine Dermal Matrix for Treatment of Chronic Ulcerations of the Midfoot Associated With Charcot Neuroarthropathy
Kavros, Steven J.

Mayo Clinic

Foot & Ankle Specialist | June 20, 2012 | Volume: 5 | Issue: 4 | Pages: 230-234

10.1177/1938640012449037 | PMID 22715495 Get It

Background. Gross deformity of the foot in Charcot neuroarthropathy can lead to collapse and subsequent ulceration, infection, amputation, or premature death. This study evaluated healing of midfoot ulcerations of Charcot neuroarthropathy using PriMatrix, a novel acellular fetal bovine dermal matrix. Methods. In this retrospective analysis, 20 patients with ulcerations of the midfoot associated with Charcot neuroarthropathy were treated with either PriMatrix in addition to standard wound care (PriMatrix group,n = 12) or standard wound care alone (control group, n = 8). All patients had chronic, nonhealing foot ulcerations of at least 2250 mm 3 for a minimum of 30 days duration. All foot ulcerations were full thickness with subcutaneous involvement. Ankle brachial index ≥0.90 and/or transcutaneous oximetry (TcPo 2 ) ≥40 mm Hg at the periulcer site was necessary for inclusion. Patients were excluded if they had acute or chronic osteomyelitis of the foot. Results. Demography, risk factors, baseline severity of Charcot neuroarthropathy, and wound volume (control 4078 mm 3 , PriMatrix 3737.5 mm 3 , P = nonsignificant) were similar between treatment groups. Mean time to healing in the PriMatrix group (116 days, 95% CI = 109-123) was significantly shorter than in the control group (180 days, 95% confidence interval [CI] = 171-188); P < .0001. A significantly faster rate of healing was observed with PriMatrix (87.9 mm 3 /wk, 95% CI = 115.2% to 60.6%) compared with control (59.0 mm 3 /wk, 95% CI = 72.8% to 45.3%); P < .0001). Conclusions. The significantly faster rate of healing and steeper slope of volume reduction in the PriMatrix group warrants further investigation into its effects on healing of neuropathic ulcerations and potential limb salvage. Levels of Evidence: Therapeutic, Level IV
Endoscopic-Ultrasound-Guided Tissue Sampling Facilitates the Detection of Local Recurrence and Extra Pelvic Metastasis in Pelvic Urologic Malignancy
Gleeson, Ferga C. , Clain, Jonathan E., Karnes, R. Jeffrey , Rajan, Elizabeth , Topazian, Mark , Wang, Kenneth K. , Levy, Michael J.

Mayo Clinic

Diagnostic and Therapeutic Endoscopy | June 19, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-6

10.1155/2012/219521 | PMID 22778538 Get It

Pelvic lymph node dissection is the gold standard for assessing nodal disease in prostate or bladder cancer and is superior to CT, MRI and PET staging. Endoscopic ultrasound (EUS) provides an alternative, less invasive method of cytohistologic material acquisition, but its performance in pelvic urologic malignancy is unknown. Therefore, our aim was to evaluate the diagnostic accuracy of EUS guided tissue sampling for these malignancies when compared to a composite cytohistologic and surgical gold standard. A median of 3 FNA passes were performed (n=19 patients) revealing a sensitivity, specificity, PPV and NPV of 94.4% (72–99), 100% (2–100), 100% (80–100) and 50% (1–98) respectively. The perirectal space was the most frequently sampled location irrespective of the primary urological cancer origin. Final diagnosis established by EUS tissue sampling included bladder cancer (n=1), bladder cancer local recurrence (n=8), bladder cancer extra pelvic metastases (n=1), prostate cancer (n=2), prostate cancer local recurrence (n=4), prostate cancer extra pelvic metastases (n=1), testicular cancer extra pelvic metastases (n=1) and a benign seminal vesicle (n=1). EUS guided sampling of the gut wall, lymph nodes, or perirectal space yields suitable diagnostic material to establish the presence of primary, local recurrence or extra pelvic metastases of pelvic urologic malignancy.
Barriers to Considering Ethical and Societal Implications of Research: Perceptions of Life Scientists
Boyce, Angie, Ladd, Jennifer M. , McCormick, Jennifer Blair , Cho, Mildred K.

Mayo Clinic

AJOB Primary Research | June 19, 2012 | Volume: 3 | Issue: 3 | Pages: 40-50

10.1080/21507716.2012.680651 | PMID 22866239 Get It

Manganese Superoxide Dismutase Regulates a Metabolic Switch during the Mammalian Cell Cycle
Sarsour, Ehab H. , Kalen, Amanda L., Xiao, Zhen , Veenstra, Timothy D. , Chaudhuri, Leena, Reigan, Philip , Buettner, Garry R. , Goswami, Prabhat C. , Venkataraman, Sujatha , Buettner, Garry R

Mayo Clinic

Cancer Research | June 19, 2012 | Volume: 72 | Issue: 15 | Pages: 3807-3816

10.1158/0008-5472.can-11-1063 | PMID 22710435 Get It

Abstract Proliferating cells consume more glucose to cope with the bioenergetics and biosynthetic demands of rapidly dividing cells as well as to counter a shift in cellular redox environment. This study investigates the hypothesis that manganese superoxide dismutase (MnSOD) regulates cellular redox flux and glucose consumption during the cell cycle. A direct correlation was observed between glucose consumption and percentage of S-phase cells in MnSOD wild-type fibroblasts, which was absent in MnSOD homozygous knockout fibroblasts. Results from electron paramagnetic resonance spectroscopy and flow cytometric assays showed a significant increase in cellular superoxide levels in S-phase cells, which was associated with an increase in glucose and oxygen consumption, and a decrease in MnSOD activity. Mass spectrometry results showed a complex pattern of MnSOD-methylation at both lysine (68, 89, 122, and 202) and arginine (197 and 216) residues. MnSOD protein carrying a K89A mutation had significantly lower activity compared with wild-type MnSOD. Computational-based simulations indicate that lysine and arginine methylation of MnSOD during quiescence would allow greater accessibility to the enzyme active site as well as increase the positive electrostatic potential around and within the active site. Methylation-dependent changes in the MnSOD conformation and subsequent changes in the electrostatic potential around the active site during quiescence versus proliferation could increase the accessibility of superoxide, a negatively charged substrate. These results support the hypothesis that MnSOD regulates a “metabolic switch” during progression from quiescent through the proliferative cycle. We propose MnSOD as a new molecular player contributing to the Warburg effect. Cancer Res; 72(15); 3807–16. ©2012 AACR.
Essential Tremor is Not a Neurodegenerative Disease
Rajput, Ali H. , Shill, Holly A. , Rajput, Alex, Adler, Charles H.

Mayo Clinic

Neurodegenerative Disease Management | June 18, 2012 | Volume: 2 | Issue: 3 | Pages: 259-268

10.2217/nmt.12.23 | PMID 23105950 Get It